Esperion Therapeutics, Inc.
Symbol: ESPR
NASDAQ
2.05
USDMarktpreis heute
-0.9875
P/E-Verhältnis
0.0209
PEG-Verhältnis
349.36M
MRK Kapital
- 0.00%
DIV Rendite
Esperion Therapeutics, Inc. (ESPR) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 497.89 | 82.2 | 124.8 | 208.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | 17.43 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 168.33 | 48.5 | 33.7 | 22.9 | |||||||||||||||||
balance-sheet.row.inventory | 202.09 | 65.6 | 35.2 | 34.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 20.89 | 4.7 | 9.9 | 62.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 902.02 | 201.1 | 246.7 | 329 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.3 | 4.7 | 1.2 | 2.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | -50.4 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | -3.72 | 0 | -42.1 | 50 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 11.52 | 4.7 | 1.3 | 52.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 913.55 | 205.8 | 247.9 | 381.6 | |||||||||||||||||
balance-sheet.row.account-payables | 99.56 | 31.7 | 23 | 17.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 38.29 | 36.4 | 0.4 | 1.4 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 1288.3 | 501.5 | 260.6 | 258.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.6 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 285.83 | 62.7 | 65.4 | 48.7 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1983.59 | 504.6 | 479.4 | 505.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.46 | 3 | 1 | 1.9 | |||||||||||||||||
balance-sheet.row.total-liab | 2480.18 | 660.8 | 571.7 | 578.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.42 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.retained-earnings | -5895.67 | -1549.3 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3256.52 | 1094.2 | -0.1 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -158.55 | 205.8 | -768.3 | -527.8 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -158.55 | - | - | - | |||||||||||||||||
Total Investments | 17.43 | 0 | 84.2 | 100.9 | |||||||||||||||||
balance-sheet.row.total-debt | 1329.61 | 540.9 | 260.9 | 260.2 | |||||||||||||||||
balance-sheet.row.net-debt | 849.15 | 458.7 | 136.2 | 51.3 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.16 | 0.2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -17.56 | 36.5 | 0 | -2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 11.96 | 12 | 15.2 | 24.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 13.68 | 13.7 | -3.4 | -52.5 | |||||||||||||||||
cash-flows.row.account-receivables | -14.77 | -14.8 | -10.8 | -10.5 | |||||||||||||||||
cash-flows.row.inventory | -30.42 | -30.4 | -0.8 | -18.3 | |||||||||||||||||
cash-flows.row.account-payables | 8.68 | 8.7 | 5.6 | -34.1 | |||||||||||||||||
cash-flows.row.other-working-capital | 50.18 | 50.2 | 2.6 | 10.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 65.52 | 11.5 | 46.5 | 35.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -135.49 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -59.9 | -50.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 42.5 | 42.5 | 68 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 42.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 42.5 | 42.5 | 8.1 | -50.5 | |||||||||||||||||
cash-flows.row.debt-repayment | -15.51 | -15.5 | -58.2 | -0.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 13.52 | 66 | 90.8 | 218.7 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 53.81 | 0 | -50.2 | 50.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 50.46 | 50.5 | 32.6 | 268.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -42.53 | -42.5 | -134.1 | -46.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 480.46 | 82.2 | 124.8 | 258.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 522.99 | 124.8 | 258.9 | 305 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.free-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.33 | 116.3 | 75.5 | 78.4 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 43.27 | 43.4 | 27 | 14.2 | |||||||||||||||||
income-statement-row.row.gross-profit | 73.06 | 72.9 | 48.5 | 64.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 86.11 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 29.82 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 248.79 | 228.5 | 228 | 291 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 271.9 | 271.9 | 255 | 305.2 | |||||||||||||||||
income-statement-row.row.interest-income | 5.11 | 4.8 | 2.6 | 0.1 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.36 | 0.2 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -154.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -155.56 | -155.6 | -179.5 | -226.7 | |||||||||||||||||
income-statement-row.row.income-before-tax | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 27.42 | 0 | 54.2 | 49.7 | |||||||||||||||||
income-statement-row.row.net-income | -236.75 | -209.2 | -287.8 | -318.8 |
Häufig gestellte Frage
Wie hoch ist die Esperion Therapeutics, Inc. (ESPR) Gesamtvermögen?
Esperion Therapeutics, Inc. (ESPR) Gesamtvermögen ist 205796000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 66219000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.628.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -1.205.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -2.035.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -1.337.
Was ist der Esperion Therapeutics, Inc. (ESPR) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -209248000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 540947000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 228466000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 82248000.000.